基本數據
| LEI | 549300IN52C2XAYTBO53 |
| CIK | 1644963 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Avenue Therapeutics, Inc.
SEC Filings (Chronological Order)
本頁面提供了一個完整的、按時間順序排列的美國證券交易委員會（SEC）申報文件列表，不包括我們在其他地方提供的所有權申報。
| May 8, 2026 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38114 AVE |
|
| May 8, 2026 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. PATENT LICENSE AGREEMENT This Agreement (this “Agreement”) is effective as of February 18, 2026 (the "EFFECTIVE DATE"), between Avenue Therapeutics, Inc. ("LICENSEE") h |
|
| March 30, 2026 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 DESCRIPTION OF CAPITAL STOCK Avenue Therapeutics, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, with $0.0001 par value (“Common Stock”). The following descriptions of our |
|
| March 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File Number 001-38114 AVENUE |
|
| February 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 18, 2026 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Numbe |
|
| February 23, 2026 |
Exhibit 99.1 Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease ATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy MIAMI, February 23, 2026 – Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a special |
|
| December 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 30, 2025 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Numbe |
|
| December 15, 2025 |
As filed with the Securities and Exchange Commission on December 15, 2025 As filed with the Securities and Exchange Commission on December 15, 2025 Registration No. |
|
| December 15, 2025 |
Calculation of Filing Fee Tables S-3 AVENUE THERAPEUTICS, INC. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward I |
|
| December 15, 2025 |
Exhibit 10.26 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. STOCK PURCHASE AGREEMENT among AXSOME THERAPEUTICS, INC., BAERGIC BIO, INC., and The STOCKHOLDERS of Baergic Bio, Inc., including, without limitation: AVENUE THERAPEUT |
|
| December 15, 2025 |
Avenue Therapeutics, Inc. 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154 Avenue Therapeutics, Inc. 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154 December 15, 2025 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: Avenue Therapeutics, Inc. Application for Withdrawal of Registration Statement on Form S-3 (File No. 333-283611) Ladies and Gentlemen: On December 4, 2024, Avenue Therap |
|
| December 5, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant. ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt |
|
| November 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 14, 2025 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Numbe |
|
| November 13, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38114 |
|
| November 12, 2025 |
Exhibit 99.1 Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics Baergic shareholders eligible to receive up to approximately $82 million in potential development, regulatory, and sales milestones plus a tiered mid-to-high single digit royalty on global net sales from Axsome MIAMI, November 6, 2025 – Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Com |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 5, 2025 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number |
|
| August 14, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38114 AVEN |
|
| May 15, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38114 AVE |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 24, 2025 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number) |
|
| April 30, 2025 |
Exhibit 10.1 Execution Copy CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. License Termination and Program Transfer Agreement by and between AnnJi Pharmaceutical Co., Ltd. and Avenue Therapeutics, Inc. dated April 24, 2025 Table |
|
| March 31, 2025 |
Subsidiaries of Avenue Therapeutics, Inc.* Exhibit 21.1 AVENUE THERAPEUTICS, INC. Subsidiaries of Avenue Therapeutics, Inc. at December 31, 2024, with jurisdiction of incorporation or formation: ● Baergic Bio, Inc. (Delaware) |
|
| March 31, 2025 |
Exhibit 19.1 Avenue Therapeutics, Inc. is subject to the following Insider Trading Policy of Fortress Biotech, Inc. (“Fortress”), which is applicable to all Fortress subsidiaries. FORTRESS BIOTECH, INC. AND SUBSIDIARIES INSIDER TRADING POLICY January 22, 2024 PERSONS COVERED This Insider Trading Policy applies to Fortress Biotech, Inc. (“Fortress”) and each of its publicly traded and private subsi |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File Number 001-38114 AVENUE |
|
| March 31, 2025 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 DESCRIPTION OF CAPITAL STOCK Avenue Therapeutics, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, with $0.0001 par value (“Common Stock”). The following descriptions of our |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 17, 2025 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number) |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 7, 2025 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number) 4 |
|
| February 14, 2025 |
JOINT FILING AGREEMENT February 14, 2025 EXHIBIT 99.1 JOINT FILING AGREEMENT February 14, 2025 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Act”), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule or regulation thereunder (including a |
|
| December 4, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Avenue Therapeutics, Inc. |
|
| December 4, 2024 |
As filed with the Securities and Exchange Commission on December 4, 2024 As filed with the Securities and Exchange Commission on December 4, 2024 Registration No. |
|
| December 4, 2024 |
Form of Indenture, between the Registrant and one or more trustees to be named. Exhibit 4.10 AVENUE THERAPEUTICS, INC. and Trustee INDENTURE Dated as of DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 3.05 and 4.02 314(b |
|
| November 29, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 26, 2024 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Numbe |
|
| November 15, 2024 |
ATXI / Avenue Therapeutics, Inc. / Fortress Biotech, Inc. - SC 13D/A Activist Investment SC 13D/A 1 tm2428627d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 5) Under the Securities Exchange Act of 1934 AVENUE THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 05360L403 (CUSIP Number) Fortress Biotech, Inc. c/o Lindsay A. Rosenwald, M.D. 1111 Kane Concourse, Suite 3 |
|
| November 14, 2024 |
Exhibit 99.1 Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - Topline data in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy anticipated around year-end 2024 Miami, FL – November 14, 2024 – Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development |
|
| November 14, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38114 |
|
| November 14, 2024 |
ATXI / Avenue Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-atxi093024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AVENUE THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 05360L403 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 14, 2024 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Numbe |
|
| September 27, 2024 |
Form of Restricted Stock Unit Agreement. Exhibit 10.1 [FORM OF] AVENUE THERAPEUTICS, INC. 2015 INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT This Restricted Stock Unit Award Agreement (this “Agreement”) is made and entered into between Avenue Therapeutics, Inc. (the “Company”) and [●] (“Grantee”), effective as of [●] (such date the “Date of Grant”). This Agreement sets forth the terms and conditions associated with the Company’s a |
|
| September 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 23, 2024 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Numb |
|
| August 9, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38114 AVEN |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2024 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number) |
|
| August 9, 2024 |
Exhibit 99.1 Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights - Last patient visit complete in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data anticipated in second half of 2024 – - Raised $4.4 million in gross proceeds from a May 2024 warrant exercise transaction - Miami, FL – August 9, 2024 – Avenue Therape |
|
| July 12, 2024 |
Exhibit FILING FEES. Calculation of Filing Fee Tables Form S-8 (Form Type) Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule(1) Amount Registered(2) Proposed Maximum Offering Price Per Unit(1) Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Equity Comm |
|
| July 12, 2024 |
As filed with the Securities and Exchange Commission on July 12, 2024 As filed with the Securities and Exchange Commission on July 12, 2024 Registration No. |
|
| June 26, 2024 |
Amendment to the Avenue Therapeutics, Inc. 2015 Incentive Plan. Exhibit 10.1 AMENDMENT TO THE AVENUE THERAPEUTICS, INC. 2015 STOCK PLAN This Amendment to the Avenue Therapeutics, Inc. 2015 Stock Plan (the “Plan”), has been adopted by the Board of Directors (the “Board”) and approved by the stockholders of Avenue Therapeutics, Inc. (the “Company”), to be effective as of June 24, 2024. WITNESSETH: WHEREAS, the Company adopted the Plan for the purposes set forth |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 24, 2024 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number) 4 |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 21, 2024 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number) 47 |
|
| May 15, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38114 AVE |
|
| May 15, 2024 |
Exhibit 99.1 Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights - Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – Miami, FL – May 15, 2024 – Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of |
|
| May 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2024 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number) 47 |
|
| May 13, 2024 |
Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT May 10, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Avenue Therapeutics, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used in thi |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2024 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number) 47 |
|
| May 10, 2024 |
PROSPECTUS SUPPLEMENT (To Prospectus Dated December 10, 2021) Up to $3,850,000 Common Stock We have entered into a sales agreement (the “sales agreement”) dated May 10, 2024, with H. |
|
| May 10, 2024 |
1,420,741 Shares of Common Stock underlying certain Common Warrants and Placement Agent Warrants Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-279125 Prospectus 1,420,741 Shares of Common Stock underlying certain Common Warrants and Placement Agent Warrants This prospectus relates to the resale by the selling stockholders (the “Selling Stockholders”) identified in this prospectus under the section “The Selling Stockholders,” or their pledgees, donees, transferees or other su |
|
| May 8, 2024 |
Avenue Therapeutics, Inc. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, Florida 33154 Correspondence. Avenue Therapeutics, Inc. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, Florida 33154 VIA EDGAR May 8, 2024 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Chris Edwards Re: Avenue Therapeutics, Inc. Registration Statement on Form S-3 (Reg. No. 333-279125) Request for Acceleration of Eff |
|
| May 8, 2024 |
United States securities and exchange commission logo May 8, 2024 Alexandra MacLean, M. |
|
| May 6, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant. ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt |
|
| May 6, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant. ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt |
|
| May 6, 2024 |
As filed with the Securities and Exchange Commission on May 3, 2024 As filed with the Securities and Exchange Commission on May 3, 2024 Registration No. |
|
| May 6, 2024 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule(1) Amount Registered(2) Proposed Maximum Offering Price Per Unit(1) Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Equity Common Stoc |
|
| May 2, 2024 |
ATXI / Avenue Therapeutics, Inc. / Davidow Robert L - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 2) Under the Securities Exchange Act of 1934 Avenue Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05360L403 (CUSIP Number) May 2, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| May 1, 2024 |
Form of New Series D Warrant (May 2024). Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 1, 2024 |
Form of Investor Inducement Letter. Exhibit 10.1 AVENUE THERAPEUTICS, INC. April 28, 2024 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Avenue Therapeutics, Inc. (the “Company”) is pleased to offer to you the opportunity to exercise the warrants to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), set forth on Exhib |
|
| May 1, 2024 |
Form of Placement Agent Warrant (May 2024). Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 1, 2024 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number) 47-4113275 (IRS Em |
|
| May 1, 2024 |
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds Exhibit 99.1 Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds MIAMI, April 29, 2024 (GLOBE NEWSWIRE) - Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the entry into definitive agreement |
|
| May 1, 2024 |
Form of New Series C Warrant (May 2024). Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| April 26, 2024 |
-12-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 25, 2024 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File N |
|
| April 26, 2024 |
EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO THE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AVENUE THERAPEUTICS, INC. Avenue Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: FIRST. The Certificate of Incorporation of the Corporation is hereby amended |
|
| April 26, 2024 |
Avenue Therapeutics Announces Reverse Stock Split EXHIBIT 99.1 Avenue Therapeutics Announces Reverse Stock Split Miami, FL – April 24, 2024 – Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will effect a 1-for-75 reverse split of its issued and outstanding common s |
|
| April 17, 2024 |
ATXI / Avenue Therapeutics, Inc. / Fortress Biotech, Inc. - SC 13D/A Activist Investment SC 13D/A 1 tm2412005d2sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 4) Under the Securities Exchange Act of 1934 AVENUE THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 05360L304 (CUSIP Number) Fortress Biotech, Inc. c/o Lindsay A. Rosenwald, M.D. 1111 Kane Concourse, Suite 3 |
|
| March 29, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 26, 2024 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number) |
|
| March 18, 2024 |
Consulting Agreement with Dr. Jay Kranzler, dated December 1, 2020.* Exhibit 10.19 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (this “Agreement”), effective as of this 1st day of December 2020 (the “Effective Date”) is by and between Jay Kranzler, M.D., Ph.D., having an address set forth below (hereinafter referred to as “Consultant”) and Baergic Bio, Inc., a Delaware corporation, having offices at 2 Gansevoort, 9th Floor, New York, NY 10014 (“Baergic”). W I T N |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File Number 001-38114 AVENUE |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 18, 2024 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number) |
|
| March 18, 2024 |
Exhibit 99.1 Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights - Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in second quarter of 2024 - - Presented positive BAER-101 preclinical data at American Epilepsy Society (AES) and American Society for Experimental Neurotherapeutics (ASE |
|
| March 18, 2024 |
Description of Securities of Avenue Therapeutics, Inc.* Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 DESCRIPTION OF CAPITAL STOCK Avenue Therapeutics, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, with $0.0001 par value (“Common Stock”). The following descriptions of our |
|
| March 18, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ¨ Preliminary Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) x Definitive Information Statement AVENUE THERAPEUTICS, INC. (Name of Registrant as S |
|
| March 18, 2024 |
Subsidiaries of Avenue Therapeutics, Inc.* Exhibit 21.1 AVENUE THERAPEUTICS, INC. Subsidiaries of Avenue Therapeutics, Inc. at December 31, 2023, with jurisdiction of incorporation or formation: ● Baergic Bio, Inc. (Delaware) |
|
| March 18, 2024 |
Exhibit 97.1 AVENUE THERAPEUTICS, INC. Clawback Policy Effective as of October 2, 2023 The Board of Directors (“Board”) of Avenue Therapeutics, Inc. (“Company”) believes that it is in the best interests of the Company and its shareholders to adopt this Clawback Policy (“Policy”) which provides for the recoupment of certain executive compensation in the event of an Accounting Restatement (as define |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 11, 2024 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number) |
|
| March 8, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: x Preliminary Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ¨ Definitive Information Statement AVENUE THERAPEUTICS, INC. (Name of Registrant as S |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 6, 2024 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number) 4 |
|
| February 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 20, 2024 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Numbe |
|
| February 23, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AVENUE THERAPEUTICS, INC. Avenue Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: FIRST. The Certificate of Incorporation of the Corporation is hereby amended |
|
| February 2, 2024 |
33,080,598 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-276671 Prospectus 33,080,598 Shares of Common Stock This prospectus relates to the resale by the selling stockholders (the “Selling Stockholders”) identified in this prospectus under the section “The Selling Stockholders,” or their pledgees, donees, transferees or other successors in interest, from time to time, of shares of our Commo |
|
| January 30, 2024 |
Avenue Therapeutics, Inc. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, Florida 33154 Avenue Therapeutics, Inc. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, Florida 33154 VIA EDGAR January 30, 2024 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Tamika Sheppard Re: Avenue Therapeutics, Inc. Registration Statement on Form S-3 (Reg. No. 333-276671) Request for Acceleration of Effective Da |
|
| January 29, 2024 |
United States securities and exchange commission logo January 29, 2024 Alix MacLean Chief Executive Officer Avenue Therapeutics. |
|
| January 29, 2024 |
our Definitive Information Statement on Schedule 14C, filed with the SEC on January 29, 2024 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ¨ Preliminary Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) x Definitive Information Statement Avenue Therapeutics, Inc. (Name of Registrant as S |
|
| January 24, 2024 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule(1) Amount Registered(2) Proposed Maximum Offering Price Per Unit(1) Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Equity Common Stoc |
|
| January 24, 2024 |
As filed with the Securities and Exchange Commission on January 24, 2024 As filed with the Securities and Exchange Commission on January 24, 2024 Registration No. |
|
| January 24, 2024 |
Form of Amendment to Third Amended and Restated Certificate of Incorporation Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AVENUE THERAPEUTICS, INC. Avenue Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: FIRST. The Certificate of Incorporation of the Corporation is hereby amended |
|
| January 17, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: x Preliminary Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ¨ Definitive Information Statement Avenue Therapeutics, Inc. (Name of Registrant as S |
|
| January 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2024 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number) |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 5, 2024 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number) |
|
| January 8, 2024 |
Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds Exhibit 99.1 Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds MIAMI, Jan. 5, 2024 (GLOBE NEWSWIRE) - Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the entry into warrant exercise |
|
| January 8, 2024 |
Form of January 2023 Investor Inducement Letter. Exhibit 10.1 AVENUE THERAPEUTICS, INC. January 5, 2024 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Avenue Therapeutics, Inc. (the “Company”) is pleased to offer to you the opportunity to exercise all of the warrants to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), issued to |
|
| January 8, 2024 |
Form of New Series B Warrant (January 2024). Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 8, 2024 |
Form of New Series A Warrant (January 2024). Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 8, 2024 |
Form of November 2023 Investor Inducement Letter. Exhibit 10.2 AVENUE THERAPEUTICS, INC. January 5, 2024 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Avenue Therapeutics, Inc. (the “Company”) is pleased to offer to you the opportunity to exercise all of the warrants to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), issued to |
|
| January 2, 2024 |
ATXI / Avenue Therapeutics, Inc. / SABBY MANAGEMENT, LLC - ATXI 13GA 1.02.24 Passive Investment SC 13G/A 1 atxi0124.txt ATXI 13GA 1.02.24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* Avenue Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05360L205 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| December 13, 2023 |
US05360L3042 / Avenue Therapeutics Inc / Davidow Robert L - SC 13G/A Passive Investment SC 13G/A 1 davidow13g.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1) Under the Securities Exchange Act of 1934 Avenue Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05360L304 (CUSIP Number) December 11, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| November 28, 2023 |
US05360L3042 / Avenue Therapeutics Inc / Davidow Robert L - SCHEDULE 13G Passive Investment SC 13G 1 davidow13g.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Avenue Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05360L304 (CUSIP Number) October 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| November 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 20, 2023 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Numbe |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 13, 2023 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Numbe |
|
| November 13, 2023 |
Exhibit 99.1 Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights - Phase 1b/2a clinical trial of AJ201 remains on track to report topline data in second quarter of 2024 - - Positive BAER-101 preclinical data accepted for presentation at American Epilepsy Society (AES) Annual Meeting - - Agreement reached with U.S. FDA on study design and analysis approa |
|
| November 13, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38114 |
|
| November 2, 2023 |
Avenue Therapeutics Announces Closing of $5.0 Million Public Offering Exhibit 99.2 Avenue Therapeutics Announces Closing of $5.0 Million Public Offering MIAMI, Nov. 2, 2023 (GLOBE NEWSWIRE) - Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the closing of its previously announced public offeri |
|
| November 2, 2023 |
Form of Series B Warrant (November 2023). Exhibit 4.2 SERIES B COMMON STOCK PURCHASE WARRANT AVENUE THERAPEUTICS, INC. Warrant Shares: [·] Issuance Date: November 2, 2023 Initial Exercise Date: November 2, 2023 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that Cede & Co. or its registered assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter se |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 31, 2023 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number |
|
| November 2, 2023 |
Exhibit 4.4 Warrant Agent Agreement This WARRANT AGENT AGREEMENT (this “Warrant Agreement”) dated as of October 31, 2023 is by and between Avenue Therapeutics, Inc, a Delaware corporation (the “Company”), and VStock Transfer, LLC (the “Warrant Agent”). WHEREAS, the Company is selling in a public offering up to (i) 3,853,400 units (the “Units”), with each Unit consisting of (x) one (1) share of com |
|
| November 2, 2023 |
Form of Pre-funded Warrant (November 2023). Exhibit 4.3 PREFUNDED COMMON STOCK PURCHASE WARRANT AVENUE THERAPEUTICS, INC. Warrant Shares: [·] Issuance Date: November 2, 2023 Initial Exercise Date: October 31, 2023 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that Cede & Co. or its registered assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter |
|
| November 2, 2023 |
Exhibit 10.1 PLACEMENT AGENCY AGREEMENT October 31, 2023 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 and Lake Street Capital Markets, LLC 920 Second Avenue South, Suite 700 Minneapolis, Minnesota 55402 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), Avenue Therapeutics, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to |
|
| November 2, 2023 |
Form of Series A Warrant (November 2023). Exhibit 4.1 SERIES A COMMON STOCK PURCHASE WARRANT AVENUE THERAPEUTICS, INC. Warrant Shares: [·] Issuance Date: November 2, 2023 Initial Exercise Date: November 2, 2023 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that Cede & Co. or its registered assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter se |
|
| November 2, 2023 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 31, 2023, between Avenue Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condit |
|
| November 2, 2023 |
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering EX-99.1 8 tm2329202d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 October 31, 2023 Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) - Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today |
|
| November 2, 2023 |
Filed Pursuant to Rule 424(b)(4) Registration Statement No. 333-274562 Prospectus 3,853,400 Units, Each Consisting of (A) One Share of Common Stock, (B) One Series A Warrant to Purchase One Share of Common Stock and (C) One Series B Warrant to Purchase One Share of Common Stock 12,780,000 Pre-Funded Units, Each Consisting of (A) One Pre-funded Warrant to Purchase One Share of Common Stock, (B) One |
|
| October 30, 2023 |
October 30, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-1004 Re: Avenue Therapeutics, Inc. Registration Statement on Form S-1, as amended File No. 333-274562 Ladies and Gentlemen: As the placement agent of the proposed offering of Avenue Therapeutics, Inc. (the “Company”), we hereby join the Company’s request for |
|
| October 30, 2023 |
Avenue Therapeutics, Inc. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, Florida 33154 Avenue Therapeutics, Inc. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, Florida 33154 VIA EDGAR October 30, 2023 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Joshua Gorsky Re: Avenue Therapeutics, Inc. Registration Statement on Form S-1 (Reg. No. 333-274562) Request for Acceleration of Effective Date |
|
| October 27, 2023 |
Avenue Therapeutics, Inc. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, Florida 33154 Avenue Therapeutics, Inc. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, Florida 33154 VIA EDGAR October 27, 2023 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Joshua Gorsky Re: Avenue Therapeutics, Inc. Registration Statement on Form S-1 (Reg. No. 333-274562) Request for Acceleration of Effective Date |
|
| October 27, 2023 |
October 27, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: Avenue Therapeutics, Inc. |
|
| October 24, 2023 |
As filed with the Securities and Exchange Commission on October 23, 2023. As filed with the Securities and Exchange Commission on October 23, 2023. Registration Statement No. 333-274562 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Avenue Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 47-4113275 (State or Other Jurisdicti |
|
| October 24, 2023 |
Form of Securities Purchase Agreement Exhibit 10.17 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2023, between Avenue Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set |
|
| October 24, 2023 |
Exhibit 4.8 [SERIES A/SERIES B] COMMON STOCK PURCHASE WARRANT AVENUE THERAPEUTICS, INC. Warrant Shares: [•] Issuance Date: [•], 2023 Initial Exercise Date: [•], 2023 THIS [SERIES A/SERIES B] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that Cede & Co. or its registered assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions herein |
|
| October 24, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Avenue Therapeutics, Inc. |
|
| October 24, 2023 |
Form of Warrant Agent Agreement Exhibit 4.10 Warrant Agent Agreement This WARRANT AGENT AGREEMENT (this “Warrant Agreement”) dated as of [•], 2023 is by and between Avenue Therapeutics, Inc, a Delaware corporation (the “Company”), and VStock Transfer, LLC (the “Warrant Agent”). WHEREAS, the Company is selling in a public offering up to (i) [•] units (the “Units”), with each Unit consisting of (x) one (1) share of common stock, p |
|
| October 24, 2023 |
Form of Placement Agency Agreement Exhibit 10.16 PLACEMENT AGENCY AGREEMENT , 2023 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 and Lake Street Capital Markets, LLC 920 Second Avenue South, Suite 700 Minneapolis, Minnesota 55402 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), Avenue Therapeutics, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggre |
|
| October 24, 2023 |
October 24, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-1004 Re: Avenue Therapeutics, Inc. Registration Statement on Form S-1, as amended File No. 333-274562 Ladies and Gentlemen: As the placement agent of the proposed offering of Avenue Therapeutics, Inc. (the “Company”), we hereby join the Company’s request for |
|
| October 24, 2023 |
Avenue Therapeutics, Inc. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, Florida 33154 Avenue Therapeutics, Inc. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, Florida 33154 VIA EDGAR October 24, 2023 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Joshua Gorsky Re: Avenue Therapeutics, Inc. Registration Statement on Form S-1 (Reg. No. 333-274562) Request for Acceleration of Effective Date |
|
| October 5, 2023 |
Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated October 5, 2023 Relating to Preliminary Prospectus dated September 29, 2023 Registration No. |
|
| October 4, 2023 |
Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated October 3, 2023 Relating to Preliminary Prospectus dated September 29, 2023 Registration No. |
|
| September 29, 2023 |
As filed with the Securities and Exchange Commission on September 29, 2023. As filed with the Securities and Exchange Commission on September 29, 2023. Registration Statement No. 333-274562 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Avenue Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 47-4113275 (State or Other Jurisdic |
|
| September 29, 2023 |
Exhibit 4.9 PREFUNDED COMMON STOCK PURCHASE WARRANT AVENUE THERAPEUTICS, INC. Warrant Shares: [•] Issuance Date: [·], 2023 Initial Exercise Date: [·], 2023 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that Cede & Co. or its registered assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at |
|
| September 29, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Avenue Therapeutics, Inc. |
|
| September 29, 2023 |
Form of Warrant Agent Agreement Exhibit 4.10 Warrant Agent Agreement This WARRANT AGENT AGREEMENT (this “Warrant Agreement”) dated as of [•], 2023 is by and between Avenue Therapeutics, Inc, a Delaware corporation (the “Company”), and VStock Transfer, LLC (the “Warrant Agent”). WHEREAS, the Company is selling in a public offering up to (i) [•]units (the “Units”), with each Unit consisting of one (1) share of common stock, par va |
|
| September 28, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 27, 2023 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Numb |
|
| September 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 27, 2023 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Numb |
|
| September 21, 2023 |
United States securities and exchange commission logo September 21, 2023 Alexandra MacLean, M. |
|
| September 18, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Avenue Therapeutics, Inc. |
|
| September 18, 2023 |
US05360L3042 / Avenue Therapeutics Inc / Fortress Biotech, Inc. - SC 13D/A Activist Investment SC 13D/A 1 tm2326316d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 3) Under the Securities Exchange Act of 1934 AVENUE THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 05360L304 (CUSIP Number) Fortress Biotech, Inc. c/o Lindsay A. Rosenwald, M.D. 1111 Kane Concourse, Suite 3 |
|
| September 18, 2023 |
As filed with the Securities and Exchange Commission on September 18, 2023. As filed with the Securities and Exchange Commission on September 18, 2023. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Avenue Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 47-4113275 (State or Other Jurisdiction of Incorporation or |
|
| September 8, 2023 |
Exhibit 10.1 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154 September 8, 2023 Fortress Biotech, Inc. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, FL 33154 Attention: Lindsay Rosenwald, MD, Chief Executive Officer Lindsay Rosenwald, MD c/o Fortress Biotech, Inc. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, FL 33154 Re: Registration Rights Dear Mr. Rosenwald, Reference is h |
|
| September 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 8, 2023 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Numbe |
|
| August 11, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38114 AVEN |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2023 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number) |
|
| August 10, 2023 |
Exhibit 99.1 Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights - First patient dosed in Phase 1b/2a clinical trial of AJ201; topline data anticipated in first half of 2024 - - Positive BAER-101 preclinical data demonstrate excellent anti-seizure activity in translational animal model; Phase 2a trial in epilepsy planned to initiate in 2024 - - Agreeme |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 17, 2023 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number) 4 |
|
| July 5, 2023 |
Form Avenue Therapeutics, Inc. Stock Option Plan Exhibit 10.1 AVENUE THERAPEUTICS, INC. 2015 INCENTIVE PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the 2015 Incentive Plan (the “Plan”) shall have the same defined meanings in this Stock Option Agreement. I. NOTICE OF STOCK OPTION GRANT Name: Address: The undersigned Optionee has been granted an Option to purchase shares of Common Stock of the Company (“Common |
|
| July 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 29, 2023 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number) 4 |
|
| June 28, 2023 |
1,108,270 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-272730 Prospectus 1,108,270 Shares of Common Stock This prospectus relates to the resale by the selling stockholders (the “Selling Stockholders”) identified in this prospectus under the section “The Selling Stockholders,” or their pledgees, donees, transferees or other successors in interest, from time to time, of shares of our Common |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 22, 2023 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number) 4 |
|
| June 23, 2023 |
Avenue Therapeutics, Inc. 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154 Avenue Therapeutics, Inc. 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154 VIA EDGAR June 23, 2023 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Alan Campbell Re: Avenue Therapeutics, Inc. Registration Statement on Form S-3 (File. No. 333-272730) Request for Acceleration of Effective Date Ladie |
|
| June 22, 2023 |
United States securities and exchange commission logo June 22, 2023 Alexandra MacLean, M. |
|
| June 16, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule(1) Amount Registered(2) Proposed Maximum Offering Price Per Unit(1) Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Equity Common Stoc |
|
| June 16, 2023 |
As filed with the Securities and Exchange Commission on June 16, 2023 As filed with the Securities and Exchange Commission on June 16, 2023 Registration No. |
|
| May 22, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 19, 2023 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number) 47 |
|
| May 12, 2023 |
Exhibit 10.9 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. License Agreement by and between Annji Pharmaceutical Co. Ltd. and Avenue Therapeutics, Inc dated February 28, 2023 Table of Contents 1. Definitions 1 2. License; Right of First Negotiation 20 |
|
| May 12, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38114 AVE |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2023 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number) 47 |
|
| May 12, 2023 |
Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights Exhibit 99.1 Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights Miami, FL – May 12, 2023 – Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate |
|
| May 12, 2023 |
Exhibit 10.10 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (the “Agreement”), dated as of February 28, 2023, is made by and among Avenue Therapeutics, Inc. a Delaware corporation (the “C |
|
| May 4, 2023 |
1,940,299 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-271208 Prospectus 1,940,299 Shares of Common Stock This prospectus relates to the resale by the selling stockholder (the “Selling Stockholder”) identified in this prospectus under the section “The Selling Stockholder,” or its pledgees, donees, transferees or other successors in interest, from time to time, of up to 1,940,299 shares of |
|
| May 1, 2023 |
Avenue Therapeutics, Inc. 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154 Avenue Therapeutics, Inc. 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154 VIA EDGAR May 1, 2023 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Alan Campbell Re: Avenue Therapeutics, Inc. Registration Statement on Form S-1 (File. No. 333-271208) Request for Acceleration of Effective Date Ladies |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant. x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant. x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| April 17, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 17, 2023 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number) |
|
| April 17, 2023 |
United States securities and exchange commission logo April 17, 2023 Alexandra MacLean, M. |
|
| April 17, 2023 |
Exhibit 99.1 Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol Miami, FL – April 17, 2023 – Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases, today anno |
|
| April 11, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-1 (Form Type) Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule(1) Amount Registered(2) Proposed Maximum Offering Price Per Unit(1) Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Equity Common Stoc |
|
| April 11, 2023 |
As filed with the Securities and Exchange Commission on April 10, 2023. As filed with the Securities and Exchange Commission on April 10, 2023. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Avenue Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 47-4113275 (State or Other Jurisdiction of Incorporation or Orga |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File Number 001-38114 AVENUE |
|
| March 31, 2023 |
Subsidiaries of Avenue Therapeutics, Inc. Exhibit 21.1 AVENUE THERAPEUTICS, INC. Subsidiaries of Avenue Therapeutics, Inc. at December 31, 2022, with jurisdiction of incorporation or formation: ● Baergic Bio, Inc. (Delaware) |
|
| March 31, 2023 |
Description of Securities of Avenue Therapeutics, Inc. Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 DESCRIPTION OF CAPITAL STOCK Authorized Capital Stock Our authorized capital stock consists of 75,000,000 shares of common stock, with $0.0001 par value (“Common Stock”), and 2,000,000 shares of Preferred Stock, with $0.0001 par value, of which 250,000 have been designate |
|
| March 30, 2023 |
Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights Exhibit 99.1 Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights Miami, FL – March 30, 2023 – Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases, today reported financial results and recent cor |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 30, 2023 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number) |
|
| March 8, 2023 |
Exhibit 99.1 Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates Company to participate in Type C meeting for IV Tramadol with FDA on March 9, 2023 Miami, FL – March 8, 2023 – Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment o |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 7, 2023 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number) 4 |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2023 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Numbe |
|
| March 2, 2023 |
Exhibit 99.1 Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy AJ201 is being evaluated in a Phase 1b/2a clinical trial in the U.S. for the rare X-linked genetic neurodegenerative disease also known as Kennedy’s Disease which curre |
|
| February 14, 2023 |
US05360L3042 / Avenue Therapeutics Inc / CVI Investments, Inc. - SC 13G/A Passive Investment SC 13G/A 1 tm235037d21sc13ga.htm SC 13G/A CUSIP No: 05360L304 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Avenue Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title |
|
| February 10, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Avenue Therapeutics, Inc. |
|
| February 10, 2023 |
Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF AVENUE THERAPEUTICS, INC. Adopted February 9, 2023 I. CORPORATE OFFICES 1.1 Registered Office The registered office of the corporation shall be in the City of Dover County of Kent, State of Delaware. The name of the registered agent of the corporation at such location is Incorporating Services, Ltd. 1.2 Other Offices The board of directors may at a |
|
| February 10, 2023 |
As filed with the Securities and Exchange Commission on February 10, 2023 As filed with the Securities and Exchange Commission on February 10, 2023 Registration No. |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 9, 2023 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number |
|
| February 3, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AVENUE THERAPEUTICS, INC. Avenue Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: FIRST. The Certificate of Incorporation of the Corporation is hereby amended |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 30, 2023 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number |
|
| February 3, 2023 |
Amendment to the Avenue Therapeutics, Inc. 2015 Incentive Plan. Exhibit 10.1 AMENDMENT TO THE AVENUE THERAPEUTICS, INC 2015 INCENTIVE PLAN This Amendment to the Avenue Therapeutics, Inc. 2015 Incentive Plan (the “Plan”), has been adopted by the Board of Directors (the “Board”) and approved by the stockholders of Avenue Therapeutics, Inc. (the “Company”), to be effective as of January 30, 2023. 1. The Plan is hereby amended by deleting Section 5.1 of the Plan i |
|
| February 1, 2023 |
Exhibit 10.7 AEGIS CAPITAL CORP. January 27, 2023 PERSONAL AND CONFIDENTIAL Dr. Alexandra MacLean Avenue Therapeutics, Inc. 1140 Avenue of the Americas, Floor 9 New York, NY 10036 Re: ATXI Shelf Takedown Dear Dr. MacLean: The purpose of this Placement Agent Agreement (this “Agreement”) is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis” or the “Placement Agen |
|
| February 1, 2023 |
Exhibit 10.5 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of January 27, 2023, between Avenue Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securiti |
|
| February 1, 2023 |
Exhibit 10.1 RD SECURITIES PURCHASE AGREEMENT This RD Securities Purchase Agreement (this “Agreement”) is dated as of January 27, 2023, between Avenue Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (including their respective successors and assigns, each a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subjec |
|
| February 1, 2023 |
Avenue Therapeutics Announces Closing of $3.25 Million Registered Direct and Private Placement Exhibit 99.2 Avenue Therapeutics Announces Closing of $3.25 Million Registered Direct and Private Placement MIAMI, Jan. 31, 2023 (GLOBE NEWSWIRE) - Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, today announced the closing of |
|
| February 1, 2023 |
Exhibit 10.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGI |
|
| February 1, 2023 |
Exhibit 99.1 Avenue Therapeutics Announces $3.25 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules Miami, FL, January 27, 2023 - Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, today announ |
|
| February 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 27, 2023 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number |
|
| February 1, 2023 |
Exhibit 10.6 Avenue Therapeutics, Inc. - Lock-up Agreement January 27, 2023 Avenue Therapeutics, Inc. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, FL 33154 Ladies and Gentlemen: The undersigned understands that Avenue Therapeutics, Inc., a Delaware corporation (the “Company”), entered into Securities Purchase Agreements (the “SPAs”) on January 27, 2023 with each purchaser (each, an “Investor |
|
| February 1, 2023 |
Form of Pre-funded Warrant (Registered Offering) (January 2023) Exhibit 10.3 PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK AVENUE THERAPEUTICS, INC. Warrant Shares: [●] Initial Exercise Date: January 27, 2023 Issue Date: January 31, 2023 THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the con |
|
| February 1, 2023 |
Exhibit 10.2 PIPE SECURITIES PURCHASE AGREEMENT This PIPE Securities Purchase Agreement (this “Agreement”) is dated as of January 27, 2023, between Avenue Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (including their respective successors and assigns, each a “Purchaser” and collectively, the “Purchasers”). WHEREAS, su |
|
| January 31, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-261520 PROSPECTUS SUPPLEMENT To the Prospectus dated December 10, 2021 448,000 Shares of Common Stock Pre-Funded Warrants to purchase up to 1,492,299 Shares of Common Stock We are offering 448,000 shares of our common stock, par value $0.0001 per share (“Common Stock”), and pre-funded warrants (“Pre-funded Warrants”) to purchase up to 1,492,299 |
|
| January 25, 2023 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 21, 2023 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number |
|
| January 25, 2023 |
Exhibit 16.1 Tel: 212-371-4446 Fax: 212-371-9374 www.bdo.com 622 Third Ave, Suite 3100 New York, NY 10017 January 25, 2023 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on January 21, 2023, to be filed by our former client, Avenue Therapeutics, Inc. We agree with th |
|
| January 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant. x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| January 6, 2023 |
ATXI / Avenue Therapeutics Inc / Fortress Biotech, Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 2) Under the Securities Exchange Act of 1934 AVENUE THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 05360L205 (CUSIP Number) Fortress Biotech, Inc. c/o Lindsay A. Rosenwald, M.D. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, FL 33154 (781) 652- |
|
| January 4, 2023 |
ATXI / Avenue Therapeutics Inc / SABBY MANAGEMENT, LLC - SABBY 13G ATXI 1.04.23 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 4, 2023 |
DEFA14A 1 tm231610d1defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant. x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commi |
|
| December 14, 2022 |
ATXI / Avenue Therapeutics Inc / Nantahala Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Avenue Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 05360L205 (CUSIP Number) December 14, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant. x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant. x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| November 10, 2022 |
Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights Exhibit 99.1 Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights New York, NY ? November 10, 2022 ? Avenue Therapeutics, Inc. (Nasdaq: ATXI) (?Avenue? or the ?Company?), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases (?CNS?), today reported financial r |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2022 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Numbe |
|
| November 8, 2022 |
PRE 14A 1 tm2229862d1pre14a.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant. x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commi |
|
| November 8, 2022 |
Exhibit 99.1 Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders New York, NY – November 8, 2022 – Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies fo |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2022 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 31, 2022 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number |
|
| October 19, 2022 |
ATXI / Avenue Therapeutics Inc / Invagen Pharmaceuticals, Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* AVENUE THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 05360L205 (CUSIP Number) A.S. Kumar General Counsel, Cipla Limited c/o InvaGen Pharmaceuticals Inc. Site B, 7 Oser Ave. Hauppauge, New York 11788 Te |
|
| October 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 18, 2022 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number |
|
| October 17, 2022 |
ATXI / Avenue Therapeutics Inc / INTRACOASTAL CAPITAL, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Avenue Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 05360L205 (CUSIP Number) October 11, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| October 17, 2022 |
CUSIP No: 05360L304 EXHIBIT II JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the shares of common stock of Avenue Therapeutics, Inc. |
|
| October 17, 2022 |
CUSIP No: 05360L304 Exhibit I LIMITED POWER OF ATTORNEY THIS LIMITED POWER OF ATTORNEY given on the 16th day of July, 2015 by CVI Investments, Inc. |
|
| October 17, 2022 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| October 17, 2022 |
ATXI / Avenue Therapeutics Inc / CVI Investments, Inc. - SC 13G Passive Investment CUSIP No: 05360L304 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* Avenue Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 05360L304 (CUSIP |
|
| October 12, 2022 |
Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering Exhibit 99.1 Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering NEW YORK, Oct. 06, 2022 (GLOBE NEWSWIRE) - Avenue Therapeutics, Inc. (Nasdaq: ATXI) (?Avenue? or the ?Company?), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, today announced the pricing of its underw |
|
| October 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 6, 2022 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number) |
|
| October 12, 2022 |
Exhibit 4.3 Warrant Agent Agreement This WARRANT AGENT AGREEMENT (this ?Warrant Agreement?) dated as of October 6, 2022 (the ?Issuance Date?) is by and between Avenue Therapeutics, Inc, a Delaware corporation (the ?Company?), and VStock Transfer, LLC (the ?Warrant Agent?). WHEREAS, pursuant to the terms of that certain Underwriting Agreement (?Underwriting Agreement?), dated October 6, 2022, by an |
|
| October 12, 2022 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT AVENUE THERAPEUTICS, INC. Warrant Shares: [?] Issuance Date: October 11, 2022 Initial Exercise Date: October 11, 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that Cede & Co. or its registered assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any ti |
|
| October 12, 2022 |
Exhibit 1.1 Underwriting Agreement October 6, 2022 Aegis Capital Corp. 1345 Avenue of the Americas, 27th Floor New York, NY 10105 Ladies and Gentlemen: Avenue Therapeutics, Inc., a Delaware corporation (the ?Company?), agrees, subject to the terms and conditions in this agreement (this ?Agreement?), to issue and sell to Aegis Capital Corp. (the ?Underwriter?) an aggregate of 3,636,365 units, with |
|
| October 12, 2022 |
Form of Pre-funded Warrant (October 2022) Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT AvENUE THERAPEUTICS, INC. Warrant Shares: [?] Issuance Date: October 11, 2022 Initial Exercise Date: October 11, 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, Cede & Co., or its registered assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the |
|
| October 12, 2022 |
Avenue Therapeutics Announces Closing of $12 Million Underwritten Public Offering Exhibit 99.2 Avenue Therapeutics Announces Closing of $12 Million Underwritten Public Offering NEW YORK, Oct. 11, 2022 (GLOBE NEWSWIRE) - Avenue Therapeutics, Inc. (Nasdaq: ATXI) (?Avenue? or the ?Company?), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, today announced the closing of its previo |
|
| October 11, 2022 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-267206 Prospectus 2,652,065 Units, each consisting of one Share of Common Stock and one Warrant to purchase Shares of Common Stock and 984,300 Pre-Funded Units, each consisting of one Pre-funded Warrant to purchase Shares of Common Stock and one Warrant to purchase Shares of Common Stock We are offering 2,652,065 units, each consisting of one s |
|
| October 6, 2022 |
FWP 1 tm2227654d1fwp.htm FREE WRITING PROSPECTUS AVENUE THERAPEUTICS, INC. ⎸ NASDAQ: ATXI ⎸ OCTOBER 2022 Corporate Overview Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. 333 - 267206 (Preliminary Prospectus dated October 6, 2022) 2 Notice & Disclaimers Free Writing Prospectus This free writing prospectus relates to the proposed public offering of securities o |
|
| October 6, 2022 |
As filed with the Securities and Exchange Commission on October 6, 2022. Registration Statement No. 333-267206 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 (Amendment No. 2) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Avenue Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 47-4113275 (State or Other Jurisdiction |
|
| October 6, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1/A (Form Type) Avenue Therapeutics, Inc. |
|
| October 5, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1/A (Form Type) Avenue Therapeutics, Inc. |
|
| October 5, 2022 |
Form of Underwriting Agreement Exhibit 1.1 Underwriting Agreement [?], 2022 Aegis Capital Corp. 1345 Avenue of the Americas, 27th Floor New York, NY 10105 Ladies and Gentlemen: Avenue Therapeutics, Inc., a Delaware corporation (the ?Company?), agrees, subject to the terms and conditions in this agreement (this ?Agreement?), to issue and sell to Aegis Capital Corp. (the ?Underwriter?) an aggregate of [?] units, with each such un |
|
| October 5, 2022 |
Avenue Therapeutics, Inc. 2 Gansevoort St., 9th Floor New York, NY 10014 CORRESP 1 filename1.htm Avenue Therapeutics, Inc. 2 Gansevoort St., 9th Floor New York, NY 10014 VIA EDGAR October 5, 2022 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Jason Drory Re: Avenue Therapeutics, Inc. Registration Statement on Form S-1 (Reg. No. 333-267206) Request for Acceleration of Effective D |
|
| October 5, 2022 |
CORRESP 1 filename1.htm October 5, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Avenue Therapeutics, Inc. (CIK: 0001644963) Registration Statement on Form S-1 (the “Registration Statement”) Reg. No. 333-267206 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Ex |
|
| October 5, 2022 |
Form of Warrant Agent Agreement Exhibit 4.6 Warrant Agent Agreement This WARRANT AGENT AGREEMENT (this ?Warrant Agreement?) dated as of [?], 2022 (the ?Issuance Date?) is by and between Avenue Therapeutics, Inc, a Delaware corporation (the ?Company?), and VStock Transfer, LLC (the ?Warrant Agent?). WHEREAS, pursuant to the terms of that certain Underwriting Agreement (?Underwriting Agreement?), dated [], 2022, by and between the |
|
| October 5, 2022 |
Exhibit 4.5 PRE-FUNDED COMMON STOCK PURCHASE WARRANT AvENUE THERAPEUTICS, INC. Warrant Shares: [?] Issuance Date: [?], 2022 Initial Exercise Date: [?], 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, Cede & Co., or its registered assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions he |
|
| October 5, 2022 |
Exhibit 4.4 COMMON STOCK PURCHASE WARRANT AVENUE THERAPEUTICS, INC. Warrant Shares: [?] Issuance Date: [?], 2022 Initial Exercise Date: [?], 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that [?] or its registered assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the da |
|
| October 5, 2022 |
As filed with the Securities and Exchange Commission on October 4, 2022. As filed with the Securities and Exchange Commission on October 4, 2022. Registration Statement No. 333-267206 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 (Amendment No. 1) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Avenue Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 47-4113275 (State or Other Jurisdiction |
|
| September 30, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 29, 2022 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Numb |
|
| September 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 22, 2022 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Numb |
|
| September 22, 2022 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AVENUE THERAPEUTICS, INC. Avenue Therapeutics, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify: FIRST. The Certificate of Incorporation of the Corporation is hereby amended |
|
| September 22, 2022 |
Exhibit 99.1 Avenue Therapeutics Announces Reverse Stock Split and Provides Regulatory Update for IV Tramadol Including Receipt of Type A Meeting Minutes from the FDA New York, NY ? September 22, 2022 ? Avenue Therapeutics, Inc. (Nasdaq: ATXI) (?Avenue? or the ?Company?), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central n |
|
| September 2, 2022 |
United States securities and exchange commission logo September 2, 2022 Alexandra MacLean, M. |
|
| August 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 31, 2022 Avenue Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38114 (Commission File Number) |
|
| August 31, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Avenue Therapeutics, Inc. |
|
| August 31, 2022 |
As filed with the Securities and Exchange Commission on August 31, 2022. As filed with the Securities and Exchange Commission on August 31, 2022. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Avenue Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 47-4113275 (State or Other Jurisdiction of Incorporation or Org |
|
| August 22, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ¨ Preliminary Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) x Definitive Information Statement Avenue Therapeutics, Inc. (Name of Registrant as S |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 15, 2022 |
? Exhibit 10.1 ? STOCK CONTRIBUTION AGREEMENT THIS STOCK CONTRIBUTION AGREEMENT (this ?Agreement?) is made and entered into as of May 11, 2022 (the ?Effective Date?), by and between Avenue Therapeutics, Inc., a Delaware corporation (?Acquirer?) and Fortress Biotech, Inc., a Delaware corporation (?Contributor?). RECITALS A.Contributor is the owner and shareholder of record of 250,000 shares of Clas |
